Advancing Targeted Drug Delivery
Sorgen Bio is an early-stage research company developing breakthrough solutions to enable targeted & precise drug delivery to the central nervous system (CNS) and beyond.
Our Mission
Harness the power of a novel biodistribution platform & deep biological expertise to develop transformative therapies for neurodegenerative, neuromuscular & metabolic diseases.
Few therapeutic options are available for patients living with severe neurological diseases (such as Parkinson's, Alzheimer's, dementia etc.)​
Challenge: crossing the Blood-Brain-Barrier
​The Blood-Brain-Barrier (BBB) is a protective & highly selectively permeable membrane that lines the blood vasculature & protects our brain from harmful substances. Given it's protective nature, it also effectively blocks entry of biologic drugs into the brain.
​
Less than 2% of small molecules can pass through the BBB, and drug discovery (irrespective of therapeutic modality) needs to take this into account during various phases of drug development.
Targeted molecules designed & tailored to traverse the BBB have the potential to unlock the true potential of various medicines & offer significant therapeutic benefits, especially in multiple neurological diseases.
Drug discovery & development for CNS diseases
​​​​​The prevalence of severe neurodegenerative disorders increases with age, and leads to a heavy burden on individuals, patients & their families as well as burgeoning socioeconomic costs.
​​
Drug delivery to the central nervous system remains extremely challenging (see article) and numerous drug research programs have failed in the clinic.
​
​Despite these setbacks, >2000 drug candidates are currently at various stages of development.
Our Approach
Cutting-edge Nanobody Platform
We are exploring the potential of nanobodies and how they can revolutionize targeted drug transport across the Blood-Brain-Barrier (BBB), unlocking efficient treatment delivery to the brain.
Advanced Drug Transport Capabilities
Our innovative solution is aimed at enabling targeted receptor-mediated transcytosis (RMT), paving the way for safe, efficacious and precise delivery of therapeutic payloads to the brain.
​
This approach to drug transport across the Blood-Brain-Barrier offers new possibilities for efficient drug transport to the central nervous system and redefining treatment strategies for neurological disorders.
Therapeutic Payload Delivery
Our platform can unlock the potential of any therapeutic payload, be it a biologic, enzyme, siRNA, anti-sense oligo (ASO), lipid nanoparticle (LNP) or virus, revolutionizing treatment approaches for CNS disorders and addressing unmet medical needs.